Skip to main content
. Author manuscript; available in PMC: 2023 Mar 2.
Published in final edited form as: Mol Cancer Res. 2022 Sep 2;20(9):1429–1442. doi: 10.1158/1541-7786.MCR-22-0085

Figure 3: Ceramide kinase inhibition decreases mutant KRAS NSCLC cell survival by increasing MMP and generation of ROS.

Figure 3:

(A, B) A549 and H838 cells (both LUAD-derived) treated with NVP 231 (0-400 nM) for 24h hours in serum-free media were subjected to MMP (A) or cellular ROS (B) assay. (C-E) Cell survival assay (C), MMP assay (D) or Western immunoblotting (E) was performed from A549 cells treated with Veh or NAC [(3-9 mM) in (C) and 6 mM in (D), (E)] for 1 hour followed by NVP231 treatment [0-400 nM in (C) and 400 nM in (D)] for 24 hours. Data are means ± SD; n = 4-6 from at least two independent occasions. *p<0.05, **p<0.005, ***p<0.0005. Scale bar = 200 μm. Unless otherwise noted by an * or depicted p-value, data are not significant between depicted groups; p>0.05.